Wordt geladen...
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
PURPOSE: We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. M...
Bewaard in:
| Gepubliceerd in: | J Clin Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Clinical Oncology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5791845/ https://ncbi.nlm.nih.gov/pubmed/29072975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.6785 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|